Tech3
Simile just closed $200M at a $2B valuation, per Whalesbook and Startup Fortune reporting. That's a 20x markup from its $100M Series A five months ago. Moonshot AI reportedly priced at $35B after the Kimi K3 launch.
Both rounds reward momentum, not unit economics. Both deserve scrutiny.
Simile: $200M for synthetic focus groups
Per available reporting, the Series B priced at $200M on a $2B post. Greenoaks led. Index Ventures, Bain Capital Ventures, and CVS Health Ventures participated. CVS Health Ventures is also a paying customer — the real strategic anchor. Founder Joon Sung Park's Stanford research sits on autonomous AI agent behavior. The product: AI-simulated respondents for marketing and product research, pitched as a replacement for traditional focus groups.
The anchor relationship matters more than the headline valuation. A healthcare incumbent of CVS's scale committing operational budget to a pre-revenue simulation platform is the kind of proof point late-stage capital actually underwrites. Comparable Aaru printed a $1B Series A in December 2025. The category is now bidding against itself.
Moonshot AI: thin disclosure, heavy number
Available data: $3.5B raised at a $35B valuation, closed after the Kimi K3 launch. Lead investors, allocation, and round structure aren't confirmed in available reporting. A 10x markup in twelve months for a Chinese frontier model company is consistent with current market rates. Whether the unit economics support it is the open question.
Chinese model labs operate under structural advantages: compute access, cloud distribution partnerships, state-aligned enterprise channels. None of that surfaces in a single headline number. Watch disclosed enterprise contracts versus announced partnerships — the gap between the two is the real signal.
What builders and LPs should track
- Burn vs. revenue. Simile's $2B mark is a function of one anchor relationship plus a bet on enterprise replication. If CVS remains the sole $1M+ contract twelve months from now, the round ages badly.
- Customer concentration. For Moonshot, the disclosed enterprise base matters more than benchmark scores. A $35B mark on a model company only holds if paying users are visible.
- Series A markup cadence. A 20x in five months is no longer an outlier. Public comps have decoupled from private rounds. Late-stage capital is paying for acceleration, not fundamentals.
Verdict
Defensible if revenue scales 5–10x in twelve months. Vapor if the customer base stays flat. The data isn't there yet.
